The relative peak effects of isoproterenol and ouabain on 
has been shown that further increases in the contractile force of the intact heart can be achieved when ouabain-induced arrhythmias are suppressed by KCI, and additional amounts of glycoside are administered. 4 Whether or not this enhancement of the performance of the heart as a muscle leads to an improvement in its performance as a pump is not known.
We sought to answer these questions by measuring changes in myocardial contractility and cardiac output produced by increasing concentrations of isoproterenol and by a continuous infusion of ouabain. The responses to the maximum dose of each drug that did not produce toxicity were compared. Also, the effects of additional doses of ouabain, which could be administered when the toxic arrhythmia induced by the glycoside was suppressed by ventricular pacing, were studied.
Methods
Seven mongrel dogs, weighing between 19 and 21 kg, were anesthetized with sodium pentobarbital (average dose, 35 mg/kg) and ventilated with a Harvard respiratory pump with a mixture of room air and 100% 0., The heart wvas exposed through a median sternotomy and suspended in a pericardial cradle. Isometric The average effects in the seven dogs of isoproterenol and ouabain on myocardial contractile force and on the maximal rate of force development (df/dt) as measured by the strain-gauge arch are summarized in figure  1 . Infusion of the peak dose of isoproterenol increased contractile force an average of 149 ± 14% (standard error of the mean difference) and increased df/dt 278 + 22% (P < 0.001). During peak isoproterenol infusion ventricular pacing (at a rate just above that caused by isoproterenol) produced small, statistically insignificant decreases in contractile force and df/ dt to 140 ± 14% and 260 ± 18% of control, respectively. Right ventricular contractile force and its first derivative then returned to control levels Figure 1 The effect in seven dogs of peak doses of isoproterenol (isoprot.) and increasing levels of ouabain on the contractile force (as measured by a strain-gauge arch sutured to the right ventricle) in millimeters of deflection and on the peak rate of force development (df/dt) in millimeters of deflection per second. Vertical bars represent standard error of the mean values. Vent. pace = ventricular pacing.
Circulation, Volume XLII, Forty minutes after the initial dose of ouabain (20 ,ug/kg) was administered, contractile force had increased by an average of 33±+ 5% (P<0.001), and df/dt rose 28 + 5% (P < 0.02). Infusion of ouabain to just short of toxicity raised contractile force to 49 ± 7% and df/dt to 35 ± 10% above control (P < 0.001). After the first appearance of ectopic activity, the heart rate in five of the animals was increased by ventricular pacing to the same frequency that had been observed in them during the infusion of peak dose of isoproterenol. This increase in heart rate from an average of 111 to 180 beats/min produced no significant change in the isometric contractile force but increased df/dt by an average of 24 + 4% (P < 0.001) above the prepacing level to values still considerably lower than those achieved by peak isoproterenol. In addition, infusion of the peak dose of isoproterenol just after the appearance of ouabain-induced arrhythmias increased contractile force and df/ dt to levels which did not differ significantly from the levels previously achieved with isoproterenol alone ( fig. 1 ). Of note, the peak dose of isoproterenol that was administered did not increase the frequency of ectopic beats nor precipitate any new ventricular arrhythmias despite the fact that rather large amounts of ouabain had already been infused.
After the glycoside-induced arrhythmias were suppressed by ventricular pacing, ouabain infusion was continued until ventricular fibrillation supervened. Prior The relative effects of isoproterenol and ouabain on left ventricular dp/dt are shown in figure 2. Comparisons were made using data in which differences in observed dp/dt could not be attributed to changes in preload as reflected in the left ventricular end-diastolic pressure. Changes in afterload as a potential influence on dp/dt were also excluded since arterial pressure was maintained at a constant level throughout each experiment. Control dp/dt averaged 1,890 ± 150 mm Hg/sec; peak dp/dt during isoproterenol infusion averaged 3,420 ± 230 mm Hg/sec compared to an average of 2,310 ± 160 mm Hg/sec with infusion of ouabain to the pre-toxic level, a difference of 32 ± 7% (P < 0.001, fig. 2A ). This greater effect of isoproterenol on dp/dt persisted even when the heart rates during the pre-toxic infusion of ouabain were increased in five animals by ventricular pacing to the same frequencies as the sinus tachyeardia produced by isoproterenol ( fig. 2B ). Since ventricular pacing per se may alter dp/dt, comparisons were made with isoproterenol data obtained during ventricular pacing.
Finall37, dp/dt at peak doses of both drugs (ventricular pacing again was employed during both ouabain and isoproterenol studies) was 25 ± 7% greater with the catecholamine than with the glycoside (P < 0.02, fig. 2C ). could not be implicated as a cause for the observed differences. Thus, it should be noted that the data in the left portion of figure 3 were obtained at comparable end-diastolic pressures for each drug. Heart rates, however, were considerably more rapid during the catecholamine infusion than during the ouabain infusion (average, 175 9 versus 109 + 7 beats/min, P < 0.001). When heart rates were equalized by ventricular pacing in five of the seven dogs, cardiac output and stroke volume were still considerably higher during peak doses of isoproterenol than with pre-toxic doses of ouabain (P < 0.05, fig. 3 Effect of increasing levels of ouabain on the same hemodynamic parameters as described in figure 3 . The effect of peak doses of isoproterenol with ventricular pacing is also shown.
of ouabain to pre-toxic levels, peak doses of isoproterenol consistently caused less cardioacceleration, and the cardiac output was significantly lower than when isoproterenol was given prior to ouabain. Heart rate during peak isoproterenol infusion averaged 183 4 beats/min prior to the administration of ouabain and 166 + 8 beats/min after its administration (P < 0.05).
Comparison of the Effects of Pre-toxic and Peak Levels of Ouabain
The infusion of ouabain to the pre-toxic level produced a significant increase in contractile force, essentially no change in stroke volume, and a small but significant decrease in cardiac output ( fig. 5) Discussion One of the major purposes of the present investigation was to determine the relative inotropic effects of isoproterenol and ouabain in the normal intact canine heart. When the effects of isoproterenol and ouabain were compared just prior to the development of toxicity, right ventricular contractile force (measured by a strain-gauge arch) was considerably greater during infusion of the catecholamine than the glycoside. Ventricular pacing successfully suppressed the ouabaininduced arrhythmias that subsequently appeared, permitting additional amounts of the glycoside to be infused. This resulted in a further increase in contractile force until ventricular fibrillation supervened and, prior to the onset of the terminal arrhythmia, contractile force reached a level comparable to that attained by peak doses of isoproterenol.
It would therefore appear that if the arrhythmic effects of ouabain are suppressed, the inotropic ceiling reached by ouabain is similar to that of isoproterenol. However, contractile force is not a primary index of the contractile state of the myocardium, since it depends on both the rate of force development, df/ dt, which reflects the intensity of the active state of the contractile elements, and on the time available to reach peak tension, which is directly proportional to the duration of the active state.7 8 When the effects of peak doses of ouabain and isoproterenol on df/dt of the isometric muscle segment and the left ventricular dp/dt were compared, both df/dt and dp/dt were significantly lower at the peak levels of ouabain. Since these twvo indices of myocardial contractility more closely reflect the intensity of the active state than does contractile force alone, the results suggest that not only is the augmentation of myocardial contractility produced by isoproterenol greater than that attained by pre-toxic amounts of ouabain, it is also of greater magnitude than the inotropic level that can be achieved by further administration of ouabain after arrhythmias are suppressed by ventricular pacing.
Since it has been shown that increases in heart rate increase the rate of development of tension, we attempted to determine whether or not the differences in the contractile response produced by isoproterenol and ouabain could be explained by the differences in heart rate which existed with the two drugs. When attempts were made to pace the ventricle at comparable rates during infusion of supra-toxic levels of ouabain, either ventricular fibrillation occurred, or contractility and cardiac output fell precipitously. However, at pre-toxic levels of ouabain, the ventricle was paced at a rate similar to that observed during peak, pre-toxic doses of isoproterenol. Although df/dt increased significantly, the level reached was still considerably lower than that achieved with isoproterenol. Despite the increase in df/dt, no further increase in isometric force developed. Thus, an increase in heart rate under these conditions caused an increase in the mean rate of tension development and, presumably, a proportionate decrease in the time to reach peak tension, so that developed tension was not altered. These findings are similar to those observed in man by Sonnenblick and coworkers9 who studied the effects of increasing Circulation, Volume XLII, Noviem,ber 1970 heart rate on the development of contractile force utilizing a strain-gauge arch sutured to the right ventricle of patients undergoing cardiac operations. In several other studies, however, alterations in frequency of contraction produced changes in the magnitude of force development as well as the velocity of contraction,10 and it would appear that the effects of frequency on force development depend on the frequency range employed, the species studied, and whether atrial or ventricular myocardium is examined." Moreover, it has been shown that digitalis glycosides prevent frequency-dependent increases in force development when administered in high doses. '2 In addition to determining the relative capacities of isoproterenol and ouabain to increase myocardial contractility, we also examined the effects of combined administration of the two drugs. When isoproterenol was administered to an animal that had already received a pre-toxic dose of ouabain, right ventricular force equaled, but did not exceed, the level it achieved from isoproterenol alone. Similar results were obtained in an earlier study in our laboratory in which peak doses of isoproterenol were infused into dogs after suppression of digitalis-induced arrhythmias by potassium chloride or diphenylhydantoin.13 This finding suggests that the peak inotropic effect achieved by the catecholamine approaches a ceiling above which the muscle cannot respond, even when its contractility has been improved with a large dose of a cardiac glycoside. It was also observed that the peak dose of isoproterenol produced less cardio-acceleration after the administration of ouabain. These findings are consistent with the observations of Mendez and associates,14 who found that the prior administration of cardiac glycosides reduced the positive chronotropic response of the intact canine heart to intravenous epinephrine and to stimulation of the cardio-accelerator nerve.
Since the inotropic response to the combination of isoproterenol and ouabain did not differ appreciably from that obtained with isoproterenol alone, it is possible that under Circulation, Volume XLII, November 1970 appropriate clinical conditions the prior administration of digitalis to a patient with cardiac failure may allow larger doses of isoproterenol to be infused without causing excessive tachycardia. The use of a combination of isoproterenol and a cardiac glycoside should be approached with caution, however, to avoid potentially serious arrhythmias.'5 Nevertheless, it is of interest that this combination of drugs, each in sub-toxic doses, did not precipitate any arrhythmias in this study. Since isoproterenol produces an appreciable tachycardia, it is possible that any tendency for glycoside-induced arrhythmias to emerge would be partly counteracted by the increase in heart rate in a manner similar to that observed with rapid ventricular pacing.
Another major purpose of this investigation was to determine the relative effects of isoproterenol and ouabain on the performance of the heart as a pump. Stroke volume and cardiac output were considerably greater with peak doses of isoproterenol alone than with pre-toxic levels of ouabain. These differences existed even when the heart rate at the pretoxic doses of ouabain was increased by pacing to the rate observed during isoproterenol infusion ( fig. 3 ). Since ventricular pacing per se may alter cardiac output, comparisons were made using data obtained with ventricular pacing during the action of both drugs. Moreover, when a peak dose of isoproterenol was given after the administration of ouabain, the resultant cardiac output and stroke volume were no greater than with the same dose of isoproterenol administered alone.
Since alterations in afterload may influence ventricular performance,"6 mean arterial pressure was maintained at a constant level with the compressed air-blood reservoir bottle. Maintenance of the same arterial pressure also prevented baroreceptor-mediated changes in myocardial contractility and ensured adequate coronary perfusion pressure throughout the experiment. This latter point is of importanoe in light of the finding of Daniell and associates17 who reported that a decrease in coronary perfusion due to the vasodilator action of isoproterenol may limit the augmentation of myocardial contractility produced by this drug.
In addition to their inotropic actions both ouabain and isoproterenol directly alter systemic vascular resistance; the glycoside causes vasoconstriction during acute administration,'8 and the catecholamine causes vasodilatation through stimulation of the beta receptors located in the peripheral arterioles.1 Liedtke and co-workers'9 have postulated that these contrasting effects on peripheral resistance could account for the difference in the magnitude of the cardiac output responses to these two drugs. However, under the experimental conditions employed in this study, it was possible to exclude the differing effects of the two drugs on peripheral resistance by maintaining arterial pressure constant with a "pressure-bottle" connected to the arterial bed. This allows a comparison of the direct effects on the performance of the heart as a pump.
The point to be emphasized in this study is that while both agents exert a positive inotropic effect, isoproterenol produces a greater stroke volume than ouabain, at the same left ventricular end-diastolic pressure and heart rate, a finding that can only be interpreted as demonstrating that isoproterenol exerts a greater effect on the pumping capacity of the heart. In other words, at the same preload, afterload, and heart rate the difference in the stroke volume responses to the two drugs appears to be due entirely to a difference in their capacities to displace the ventricular function curves upward and to the left.
A previous study demonstrated that a further increment in myocardial contractile force could be achieved when ouabaininduced arrhythmias were suppressed by KCI and additional amounts of glycoside were administered.4 These findings suggested that under appropriate clinical conditions it might be advisable not to discontinue treatment with digitalis if the arrhythmia could be controlled by KCI. In the present investigation it was observed that as with KCI, toxic arrhythmias can be suppressed with ventricular pacing, allowing the administration of additional amounts of glycoside and a further increment in contractile force. However, this was associated with what must be interpreted as an impairment in the capacity of heart to function as a pump, since stroke volume and cardiac output both fell despite a substantial increase in left ventricular end-diastolic pressure.
The cause of this deterioration in ventricular performance despite an apparent increase in myocardial contractility is unclear. It is possible that these doses of ouabain impaired myocardial relaxation, altering the relationship between left ventricular end-diastolic pressure and left ventricular end-diastolic fiber length. Thus, with these doses of ouabain the ventriclie might be ejecting from a shorter enddiastolic fiber length, even though enddiastolic pressures were the same or higher than during the control period.
